concizumab   Click here for help

GtoPdb Ligand ID: 11182

Synonyms: Alhemo® | Anti-TFPI | mab2021 | NN7415
Approved drug
concizumab is an approved drug (Health Canada (2023))
Compound class: Antibody
Comment: Concizumab is a clinical stage anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. It is a humanised IgG4 construct that was developed by Novo Nordisk as a novel therapeutic for genetic bleeding disorders [2]. Concizumab binds to the Kunitz-type protease inhibitor (KPI) 2 domain of TFPI and blocks its interaction with the active site of FXa [1]. TFPI is an endogenous anticoagulant protein whose pharmacological inhibition restores hemostasis [7].
Classification Click here for help
Compound class Antibody
Approved drug? Yes (Health Canada (2023))
International Nonproprietary Names Click here for help
INN number INN
9636 concizumab
Synonyms Click here for help
Alhemo® | Anti-TFPI | mab2021 | NN7415
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 447
Other databases
GtoPdb PubChem SID 434122242
Search PubMed clinical trials concizumab
Search PubMed titles concizumab
Search PubMed titles/abstracts concizumab